{
  "symbol": "AMGN",
  "price": 297.4,
  "beta": 0.477,
  "volAvg": 2223442,
  "mktCap": 160108814487,
  "lastDiv": 9.39,
  "range": "253.3-335.88",
  "changes": -1.1,
  "companyName": "Amgen Inc.",
  "currency": "USD",
  "cik": "0000318154",
  "isin": "US0311621009",
  "cusip": "031162100",
  "exchange": "NASDAQ Global Select",
  "exchangeShortName": "NASDAQ",
  "industry": "Drug Manufacturers - General",
  "website": "https://www.amgen.com",
  "description": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh√ßet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",
  "ceo": "Robert A. Bradway",
  "sector": "Healthcare",
  "country": "US",
  "fullTimeEmployees": "28000",
  "phone": "805 447 1000",
  "address": "One Amgen Center Drive",
  "city": "Thousand Oaks",
  "state": "CA",
  "zip": "91320-1799",
  "dcfDiff": -586.58521,
  "dcf": 882.3487088280499,
  "image": "https://images.financialmodelingprep.com/symbol/AMGN.png",
  "ipoDate": "1983-06-17",
  "defaultImage": false,
  "isEtf": false,
  "isActivelyTrading": true,
  "isAdr": false,
  "isFund": false
}